Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety


23 Nov 2019


Poster display session


Tumour Site

Hepatobiliary Cancers


Takayoshi Oikawa


Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422


T. Oikawa, K. Yusa, T. Okamoto, M. Yonezawa, T. Satou, T. Abe, K. Endo, K. Sawara, H. Kuroda, Y. Takikawa

Author affiliations

  • Division Of Hepatology, Department Of Internal Medicine, Iwate Medical University School of Medicine, 020-8505 - Morioka/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 165P


Lenvatinib is a new first-line molecular target drug for hepatocellular carcinoma (HCC) that is available worldwide. We evaluated the efficacy and safety of lenvatinib for unresectable HCC.


This study population included thirty-seven patients that we could follow from 42 patients who received lenvatinib between April 2018 and May 2019 in our hospital. We evaluated the lenvatinib treatment profile, the clinical response (according to mRECIST), adverse events (according to CTCAE v.4.0), progression free survival (PFS), overall survival (OS), conversion therapy and the tumor response after progressive disease (PD) and serious adverse events (sAEs).


The study population included 34 male patients (91.9%). Eleven patients were positive for HBV, 14 were positive for HCV, 6 had a history of alcohol intake. The Child Pugh scores (CPS) were as follows: 5 (n = 27), 6 (n = 7), 7(n = 3). Fifteen patients had BCLC stage B and 22 had C. The reasons for lenvatinib included TACE failure/refractoriness (35.3%), vascular invasion (32%), extrahepatic spread: (27.0%), PD after other molecular target therapies (16.2%) . The initial dose was 12 mg (90%) in patients with a body weight of > 60 kg, 8 mg (68.8%) in patients with a body weight of < 60 kg; in these two groups, 50.0% and 66.6% of patients received a half-dose reduction after one month. The tumor responses were classified as follows: objective response rate (ORR), 35.1%; disease control rate (DCR), 70.3%; PFS, 7.3 months (95% CI 4.9-11.2); OS, the median OS was not reached. There was no significant differences in the CPS between before and after therapy (p = 0.68). The rates of AEs (any grade/grade ≥3) were as follows: hypertension (37.8/0%), protein urea (29.7/13.5%), hypothyroidism (16.2/0%), fatigue (8.1/2.7%), hand-foot skin reaction (5.4/0%), hepatic encephalopathy (8.1%), respectively. The ORR and DCR of the grade ≥3 and grade <2 groups did not differ to a statistically significant extent. In the grade ≥3 group, 4 patients obtained a clinical benefit, however could not receive chemotherapies because of a poor performance status (≥3).


Lenvatinib is good therapeutic drug for advanced HCC, however it is very important to pay attention to sAEs in patients who show a clinical benefit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.